Search Results

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $52 billion of equity capital under management, is pleased to announce the sale of its portfolio company Taconic Biosciences (“Taconic” or the “Company”) to Avista Capital Partners (“Avista”).

Avista Capital Partners, a leading private equity firm focused exclusively on healthcare, announced its acquisition of Taconic Biosciences, a leading provider of genetically engineered research models and related services, from H.I.G. Capital.

Taconic Biosciences has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors known to confound results in antibody-based therapy studies.

Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India.